article
<bold>Background:</bold>Deployed military members may be more prone to developing chronic upper respiratory conditions than their non-deployed counterparts, which may be related to exposure to higher levels of air pollution, harsh environments, and foreign dust storms <bold>Aim:</bold>To evaluate the adherence to allergen immunotherapy (AIT) with sublingual immunotherapy (SLIT) in allergic patients. <bold>Methods:</bold>It was a retrospective study, focused on records of patients follow-up for allergic rhinitis(AR) and asthma. Adherence was determined as the accomplishment of 3 years of SLIT. <bold>Results:</bold>110 records were consulted. The average age of patients was 29.2 years.66 patients were men (60%).91 patients(82.7%)were diagnosed as having asthma,78 patients(70.9%) had concomitant AR and asthma and 19 patients(17.2%)had AR,with a median duration of disease 3.4 years. House dust mites were the most important causes of allergic sensitization(93.3%). The median duration of SLIT was 20.7 months(1–60) and a total of 35 patients(31.8%) dropped out of SLIT before 3 years of treatment were completed. The main reasons for discontinuation in patients who dropped out were: undesirable effects 13 cases(11.8%), feeling that treatment was ineffective 9 cases(8.1%), forced discontinuation due to pregnancy 3 cases(2.7%),or improvement 10 cases(9%). Sublingual immunotherapy (SLIT) is associated more with local side effects, but no serious systemic effects were noted, notably no cases of anaphylactic shock, angioedema or moderate or severe asthma attacks. <bold>Conclusion:</bold>Adherence is crucial for AIT efficacy. It still needs to be brought to the attention of healthcare professionals especially in the early stages of treatment.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1183/13993003.congress-2024.pa2187
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.